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Abstract
Background: The magnitude and the prognostic impact of recovering left ventricular ejection fraction 
(LVEF) in patients with heart failure (HF) and systolic dysfunction is unclear. The aim of this study 
was to evaluate the clinical characteristics and prognosis of patients with HFrecEF in an HF population.
Methods: 449 consecutive patients were selected with the diagnosis of HF and an evaluation of LVEF 
in the 6 months prior to selection who were referred to two HF units. Patients with systolic dysfunction 
were only considered if a second echocardiogram was performed during the follow-up. 
Results: At the time of diagnosis, 207 patients had LVEF > 40% (HFpEF) and 242 had LVEF  
≤ 40% (HFrEF). After 1 year, the LVEF was re-evaluated in all 242 patients with a LVEF ≤ 40%: in 
126 (52%), the second LVEF was > 40% (HFrecEF), and the remaining 116 (48%) had LVEF ≤ 40% 
(HFrEF). After 1800 ± 900 days of follow-up patients with recovered LVEF had a significantly lower 
mortality rate (HFpEF vs. HFrecEF: hazard ratio [HR] = 2.286, 95% confidence interval [95% CI] 
1.264–4.145, p = 0.019; HFrEF vs. HFrecEF: HR = 2.222, 95% CI 1.189–4.186, p < 0.001) and 
hospitalization rate (HFpEF vs. HFrecEF: HR = 1.411, 95% CI 1.046–1.903, p = 0.024; HFrEF 
vs. HFrecEF: HR = 1.388, 95% CI 1.002–1.924, p = 0.049). The following are predictors of LVEF 
recovery: younger age, lower functional class, treatment with renin–angiotensin–aldosterone system 
inhibitors and beta-blockers, absence of defibrillator use, and non-ischemic etiology.
Conclusions: Patients with HF and reduced LVEF who were re-evaluated after 1 year, had significant 
improvement in their LVEF and had a more favourable prognosis than HF with preserved and reduced 
ejection fraction. (Cardiol J 2018; 25, 3: 353–362)
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Introduction
The main terminology used to describe heart 
failure (HF) is historical and is based on left ven-
tricular ejection fraction (LVEF) measurement 
which determines different etiologies, demograph-
ics, comorbidities, and response to therapies [1]. 
The 2012 European Society of Cardiology (ESC) 
Heart Failure Guidelines classified patients with 
HF using a cut-off point < 50% for HF with reduced 
LVEF (HFrEF) and ≥ 50% for HF with preserved 
LVEF (HFpEF), but the therapeutic recommenda-
tions were specific only for patients with LVEF 
≤ 40% [2, 3]. 
The new 2016 ESC Heart Failure Guidelines 
propose a new classification according to the level 
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of LVEF, as follows: HFrEF is < 40%, mid-range 
HF is an LVEF range 40–49%, and HFpEF is 
≥ 50% [4]. Currently, there is limited information 
available about the clinical, prognostic, and thera-
peutic implications of this classification [5].
In addition to clinical characterization and 
therapeutic properties, HF classification based on 
LVEF allows the identification of groups of patients 
with differences in prognosis. HFrEF patients, in 
particular, have a higher mortality rate, but a simi-
lar mortality rate between HFrEF and HFpEF has 
been described [3, 6].
Left ventricular ejection fraction is known to 
change during the natural course of the disease and 
HF with a recovered ejection fraction (HFrecEF) 
has recently been identified. HFrecEF includes 
patients who initially present with depressed LVEF 
and who recover to a value > 40%. Some studies 
suggest that this new type of HF may be a different 
clinical entity with a particular pattern of biomark-
ers, comorbidities, and a better mid-to-long-term 
prognosis, suggesting that these patients may have 
entered into a phase of disease remission [7–14].
The aim of this study was to evaluate the 
clinical characteristics and prognosis of HFrecEF 
patients within an HF population.
Methods
Study population
This was a retrospective cohort study of 596 
consecutive patients who were referred for first 
time to a HF unit in the Cardiology Department 
at two Spanish hospitals between September 2007 
and January 2014. The study was approved by the 
local bioethical committee and all patients gave 
their informed consent. HF diagnostic was made 
in accordance with the 2012 ESC Heart Failure 
Guidelines [2]. 
Patients excluded were those with specific 
infiltrative or restrictive cardiomyopathies, HF due 
to adult congenital heart disease and patients with 
primary right-sided disease. Thirty-seven patients 
were excluded because they did not have LVEF 
data in the 6 months prior to inclusion and 110 
patients with HFrEF were excluded because they 
were not assessed for LVEF at follow-up. Thus, 449 
patients in stable conditions were included in the 
analyses and classified according to their LVEF, as 
follows: 207 with HFpEF (LVEF > 40%) and 242 
with HFrEF (LVEF ≤ 40%). 
After a mean of 1 year (median, 1.51 years) 
from the beginning of the study, all included HFrEF 
patients had a second echocardiographic assess-
ment performed in a situation of clinical stability 
and optimal medical treatment. After this control, 
126 patients had LVEF > 40% (HFrecEF) and 116 
maintained a LVEF ≤ 40% (HFrEF) (Fig. 1).
For all included patients, detailed informa-
tion was gathered from their medical history and 
appropriate physical examination information was 
obtained from their charts, this information was 
recorded in a database. In addition, blood samples 
were obtained for local laboratory analysis and LVEF 
was estimated using the Simpson method according 
to current international recommendations [15]. HF 
was defined as being ischemic in etiology if any of 
the following criteria were satisfied: prior admission 
because of an acute coronary event (acute myocar-
dial infarction or unstable angina), prior surgical or 
percutaneous myocardial revascularization, pres-
ence of myocardial infarction on electrocardiogram 
or echocardiogram, or significant coronary disease 
detected by angiography. Interventions before 
inclusion in the study, such as device implantation 
(implantable cardioverter defibrillator [ICD] and/ 
/or cardiac resynchronization therapy [CRT]), and 
previous revascularization were recorded. 
Figure 1. Flowchart of patients included in the study; 
HFrEF — heart failure with remained reduced left ven-
tricular ejection fraction; HFpEF — heart failure with 
preserved left ventricular ejection fraction; HFrecEF — 
heart failure with recovered left ventricular ejection frac-
tion; LVEF — left ventricular ejection fraction.
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Follow-up 
All patients were followed for a median of 
1800 ± 900 (mean ± standard deviation) days. The 
primary endpoints were death or hospitalization for 
any cause. Interventions with a prognostic impact on 
the course of the disease (device implantation, revas-
cularization or cardiac transplantation) were recorded.
Statistical analysis
Patient characteristics were analyzed using 
statistical inference as follows: c2 test, Student’s 
t-test, ANOVA, Fisher exact test, and the Kruskal-
-Wallis test.
Event-free survival curves were calculated 
using the Kaplan-Meier method, and differences 
between the curves were evaluated using the 
log-rank test. Univariate and multivariate Cox 
regression analyses were used to calculate the 
estimated hazard ratio (HR) with a 95% confidence 
interval (CI) in where appropriate. The variables 
were entered into a multivariate model for factors 
with a p value of ≤ 0.05 in the univariate analysis. 
A multivariate analysis, such as a binary logistic 
regression, was used to determine the variables 
with independent prognostic significance in the 
LVEF recovery. This analysis included variables 
that showed significant differences in the univariate 
analysis. The Statistical Package for Social Science 
(SPSS) for Windows, version 15.0 (software SPSS 
Inc.; Chicago, Illinois, United States) was used 
for all statistical analysis. A p value of < 0.05 was 
considered to be statistically significant
Results
Baseline characteristics 
When the baseline characteristics of HpEF, 
HFrEF and HFrecEF patients were analyzed, 
observations revealed statistically significant dif-
ferences in age, sex, smoking, previous myocardial 
infarction, previous percutaneous revasculariza-
tion, previous device (ICD/CRT) implantation, 
systolic blood pressure, New York Heart Asso-
ciation (NYHA) class, heart rate, QRS duration, 
presence of left bundle branch block, pro B-type 
natriuretic peptide (proBNP) levels, HF etiology, 
and treatment with angiotensin converting enzyme 
inhibitors (ACEIs), beta-blockers, aldosterone 
antagonists, statins, acetylsalicylic acid (ASA), 
clopidogreland oral anticoagulation (Table 1). 
Patients with HFrecEF were younger, had 
a lower percentage of previous revascularization 
and use of devices, with a less advanced func-
tional class (no patient had NYHA IV), and a lower 
prevalence of ischemic etiology compared with 
HFpEF and HFrEF. These patients had greater 
use of ACEIs and less use of anticoagulants and 
anti-platelet medications.
Characteristics of patients not re-evaluated 
were also analyzed (Suppl. Table 1) and it was 
found that these patients were more likely to be 
older, with higher levels of proBNP and lower lev-
els of hemoglobin and were treated more frequently 
with diuretics and less with optimal medical treat-
ment compared with revaluated patients.
LVEF values
Table 1 shows the mean baseline LVEF in the 
three groups. The mean recovery was +10.31 ± 
± 12.95% SD (range, −18% to +50%). The LVEF 
did not change or worsened in 61 (25.4%) patients, 
and recovery was between 0% and 10% in 64 
(26.6%) patients, between 10% and 20% in 60 
(24.6%) patients, and > 20% in 57 (23.4%) patients. 
Follow-up
The 449 patients were followed up for a me-
dian of 1800 ± 900 days. During this time, statisti-
cally significant differences were observed for device 
implantation, which was greater in patients who 
maintained a reduced LVEF. For these patients, there 
were 27 defibrillator implants in HFrEF patients 
(20.1%) compared with 3 in HFrecEF patients (2.8%; 
p < 0.001), 19 resynchronizer implants in HFrEF pa-
tients (14.2%) compared with 3 in HFrecEF patients 
(2.8%; p < 0.001), and 13 defibrillator-resynchronizer 
implants in HFrEF patients (9.7%) compared with 1 
in HFrecEF patients (0.9%; p < 0.001).
There were 165 (36.7%) patients in this study 
who died. There were 100 (50.3%) deaths in the 
HFpEF group, 43 (42.2%) in the HFrEF group, 
and 22 (20.2%) in the HFrecEF group (p < 0.01). 
Survival time was higher in HFrecEF patients 
(5.2 ± 1.94 years) than in HFrEF patients (5.65 ± 
± 2.25 years) and HFpEF patients (4.97 ± 2.46 years; 
p < 0.001).
During follow-up, 312 (69.4%) patients re-
quired hospitalization; 160 (80.4%) in the HFpEF 
group, 84 (82.4%) in the HFrEF group, and 68 
(62.4%) in the HFrecEF group (p < 0.001). Time 
free from hospitalization was higher in HFrecEF 
patients (3.46 ± 2.26 years), compared to HFpEF 
patients (2.71 ± 2.49 years) and HFrEF patients 
(2.56 ± 2.24 years; p < 0.001).
Kaplan-Meier curves and log-rank tests for 
death and hospitalization showed statistically 
significant differences between the three groups 
(p < 0.005 for both comparisons; Fig. 2A, B).
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Table 1. Baseline characteristics of the population.
HFpEF (n = 207) HFrEF (n = 116) HFrecEF (n = 126) P
Demographic and medical history
Age [years] 71 ± 10 66 ± 12 63 ± 12 < 0.001
Male 120 (58%) 89 (76.7%) 92 (73%) < 0.001
Medical history: 
Tobacco use: < 0.001
Current 138 (66.7%) 56 (48.3%) 61(48.4%)
Former 8 (3.9%) 22 (19%) 24 (19%)
Never 61 (29.1%) 38 (32.8%) 41 (32.5%)
Alcohol 35 (17%) 25 (21.6%) 40 (35.7%) 0.007
Hypertension 133 (64.3%) 33 (54.3%) 69 (54.8%) 0.11
Diabetes mellitus 67 (32.4%) 39 (33.6%) 41 (32.6%) 0.97
Peripheral arterial disease 13 (6.3%) 9 (7.8%) 7 (5.3%) 0.51
Previous stroke 11 (5.3%) 7 (6%) 8 (6.3%) 0.91
Previous ACS 31 (15%) 36 (31%) 13 (10.3%) < 0.001
Previous HF admission 146 (70.5%) 79 (68.1%) 81 (64.3%) 0.495
Previous stent placement 27 (13%) 29 (25%) 12 (9.5%) 0.012
Previous CABG 21 (10.1%) 14 (12.1%) 9 (7.1%) 0.78
Previous defibrillator 2 (1%) 18 (15.5%) 3 (2.8%) < 0.001
Previous CRT 1 (0.5%) 4 (3.4%) 2 (1.6%) 0.003
Physical examination and supplementary tests
NYHA class: 0.015
I 38 (19.8%) 16 (13.8%) 25 (19.8%)
II 120 (58%) 72 (62.1%) 90 (71.4%)
III 48 (23.2%) 25 (21.6%) 11 (8.7%)
IV 1 (0.5%) 3 (2.6%) 0 (0%)
Baseline HR [bpm] 75.89 ± 19.37 74.69 ± 14.77 73.31 ± 16.65 0.43
Baseline SBP [mmHg] 132.9 ± 21.81 120.69 ± 19.8 128.64 ± 22.12 < 0.001
Baseline DBP [mmHg] 78.63 ± 14.38 76.64 ± 13.32 78.99 ± 14.491 0.37
Body mass index [kg/m2] 32 ± 21 27 ± 5 28 ± 4 0.017
ProBNP [pg/m] 1906.21 ± 2123.23 2337.25 ± 24490.04 1210.40 ± 1293.23 0.001
Creatinine [mg/dL] 1.17 ± 0.38 1.17 ± 0.39 1.13 ±0.37 0.61
Hemoglobin [g/dL] 13.7 ± 1.09 13.3 ± 1.61 13.5 ± 1.71 0.90
Sodium [meq/L] 138.4 ± 3.4 138.5 ± 3.0 138.3 ± 3.0 0.90
Anemia 58 (28%) 24 (21%) 27 (21%) 0.21
Heart rhythm: < 0.001
SR 81 (39.5%) 75 (65.2%) 85 (68%)
AF 104 (50.7%) 27 (23.5%) 28 (22.4%)
LBBB 23 (11.6%) 38 (37.3%) 20 (18.3%) < 0.001
QRS duration [ms] 114.4 ± 34.2 138.4 ± 36.6 120.2 ± 30.2 < 0.001
Baseline LVEF [%] 56.4 ± 9.5 29.1 ± 7.3 31.3 ± 6.1 < 0.001
Etiology and baseline treatment
Etiology:
Ischemic heart disease 44 (21.3%) 57 (49.1%) 25 (19.8%)
Valvular 41(19.8%) 10 (8.6%) 10 (7.9%)
Hypertrophic cardiomyopathy 6 (2.9%) 9 (7.8%) 7 (5.6%)
Enolic 17 (8.2%) 7 (6.2%) 26 (20%)
Hypertension 58 (28%) 19 (16.4%) 34(27%)
Others 43 (20%) 14 (12%) 78 (19%) < 0.001
Diuretics 170 (82.1%) 96 (82.2%) 92 (73%) 0.27
ACEIs or ARBs 158 (76.3%) 102(87.9%) 113 (90.4%) < 0.001
Beta-blockers 119 (57.1%) 97 (83.6%) 98 (77.8%) < 0.001
MRA 81 (39.1%) 63 (54.3%) 52 (41.3%) 0.025
Statins 74 (35.7%) 59 (51.8%) 48 (38.4%) 0.017
Oral anticoagulation 103 (49.8%) 40 (34.5%) 39 (31%) 0.001
ASA 69 (33.3%) 48 (41.4%) 50 (39.7%) 0.021
Clopidogrel 19 (9.2%) 23 (19.8%) 15 (11.9%) 0.007
ACS — acute coronary syndrome; ACEIs — angiotensin-converting enzyme inhibitors; AF — atrial fibrillation; ASA — acetylsalicylic acid; 
ARBs — angiotensin receptor blockers; CABG — coronary artery bypass graft; CRT — cardiac resynchronization therapy; DBP — diastolic 
blood pressure; HF — heart failure; HFrEF — heart failure with remained reduced left ventricular ejection fraction; HFpEF — heart failure with 
preserved left ventricular ejection fraction; HFrecEF — heart failure with recovered left ventricular ejection fraction; HR — heart rate; LBBB — 
left bundle branch block; LVEF — left ventricular ejection fraction; MRA — mineralcorticoid receptor antagonists; NYHA — New York Heart 
Association; proBNP — pro-B-type natriuretic peptide; SBP — systolic blood pressure; SR — sinus rhythm
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The patient prognosis was also evaluated 
according to the percentage of change in LVEF. 
The subgroup that recovered LVEF > 20% had 
a higher survival rate, although this increase was 
not statistically significant (p = 0.08), and had 
a lower percentage of hospitalizations (p < 0.001; 
Fig. 3A, B). 
The group of not re-evaluated patients had 
higher mortality (43,1%) compared with the re-
evaluated group (8.5%, p < 0.001) and had no 
differences in terms of readmissions (63.3% vs. 
72%, p = 0.14) (Fig. 4).
Independent predictors of mortality 
An analysis was performed using Cox regres-
sion to identify independent predictors of mortality. 
Only the variables with statistical significance were 
included in the univariate analysis. The variables 
used were HFrecEF, age, sex, smoking, previous 
myocardial infarction or revascularization, previ-
Figure 3. Survival curve in terms of mortality (A) and 
hospitalization (B) as a function of the percentage of 
recovered left ventricular ejection fraction.
Figure 2. Survival curve in terms of mortality (A) and 
hospitalization (B) in heart failure with remained re-
duced left ventricular ejection fraction (HFrEF), heart 
failure with preserved left ventricular ejection fraction 
(HFpEF) and heart failure with recovered left ventricular 
ejection fraction (HFrecEF).
A
B
A
B
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ous device implantation, systolic blood pressure, 
NYHA III–IV, heart rhythm, QRS duration, left 
bundle branch block, proBNP levels, HF etiology, 
ACEIs, beta-blockers, mineralocorticoid receptor 
antagonists, statins, ASA, clopidogrel, and oral 
anticoagulation.
Left ventricular ejection fraction recovery 
continued to be an independent prognostic variable 
for mortality. Thus, HFpEF patients had a risk of 
death that was 2.28-times higher than that of pa-
tients with HFrecEF, and HFrEF 2.2-times higher 
than that of patients with HFrecEF. 
Other independent variables with prognostic 
influence were age and proBNP level (Table 2).
Independent predictors of hospitalization
The same variables as in the analysis per-
formed for mortality were used in this analysis 
for hospitalization. The LVEF recovery remained 
an independent prognostic variable on the hos-
pitalization-free survival, compared with HFpEF 
and HFrEF.
Other independent prognostic variables for 
hospitalization-free survival were age and NYHA 
categories III and IV (Table 3).
Independent prognostic factors for LVEF 
recovery
A multivariate analysis was performed to 
determine which variables independently predict 
LVEF recovery.  The variables that were signifi-
cantly different were initially compared between 
the HFrEF and HFrecEF groups, as follows: age, 
sex, alcohol consumption, ischemic etiology, prior 
Table 2. Indepedent predictors of mortality.
Hazard  
ratio
95%  
confidence  
interval
P
Age 1.051 1.028–1.075 < 0.001
proBNP 1.000 1.000–1.000 < 0.001
HFpEF  
vs. HFrecEF
2.286 1.264–4.145 0.019
HFrEF  
vs. HFrecEF
2.222 1.189–4.186 < 0.001
HFrEF — heart failure with remained reduced left ventricular ejec-
tion fraction; HFpEF — heart failure with preserved left ventricular 
ejection fraction; HFrecEF — heart failure with recovered left ven-
tricular ejection fraction; proBNP — pro-B-type natriuretic peptide
Table 3. Independent predictors of hospitalization.
Hazard  
ratio
95%  
confidence  
interval
P
Age 1.014 1.003–1.024 0.011
NYHA III–IV 1.541 1.166–2.037 0.002
HFpEF  
vs. HFrecEF
1.411 1.046–1.903 0.024
HFrEF  
vs. HFrecEF
1.388 1.002–1.924 0.049
HFrEF — heart failure with remained reduced left ventricular ejec-
tion fraction; HFpEF — heart failure with preserved left ventricular 
ejection fraction; HFrecEF — heart failure with recovered left ven-
tricular ejection fraction; NYHA — New York Heart Association
A
B
Figure 4. Survival curves in terms of mortality (A) and 
hospitalization (B) in heart failure with remained re-
duced left ventricular ejection fraction (HFrEF) revalu-
ated and not revaluated patients.
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defibrillator, NYHA III-IV, systolic blood pressure, 
beta blockers, aldosterone antagonists, statins, and 
defibrillator and/or resynchronizer implantation 
during follow-up. 
The NYHA class III–IV, treatment with ACEIs 
and beta-blockers, ischemic etiology and previous 
defibrillator implantation were found to be predic-
tors of recovery and non-recovery (Table 4).
Discussion
The data showed that the HFrecEF popula-
tion has a different clinical profile (demographics, 
comorbidities, and symptom severity) compared 
with HFrEF and HFpEF populations. Patients who 
experienced LVEF recovery have an excellent 
prognosis in terms of mortality and hospitalization, 
particularly in those patients with a LVEF recovery 
higher than 20%.
A younger age, better NYHA functional class, 
treatment with ACEIs and beta-blockers, non-
ischemic etiology, and the previous ICD implan-
tation follow-up were independent predictors of 
LVEF recovery. 
The present results suggest that HFrecEF 
represents a separate clinical entity with clini-
cal and prognosis differences compared with the 
classic groups, and it is also believed that it is 
a distinct category along the HF continuum. These 
observations indicate that LVEF may be considered 
to be a guide-element for therapy optimization and 
follow-up in the same way that was proposed for 
natriuretic peptides [4].
Punnoose et al. [16] reported that nearly 30% 
of patients in their registry, who had normal LVEF 
on echocardiography, previously had a reduced 
LVEF, and they may represent a sub-group of HF 
patients with favourable cardiac and vascular re-
modeling [11]. 
According to the “cancer model”, HFrecEF 
patients could have a process of disease remission 
because of reverse remodeling that is characterized 
by an improvement in LVEF and a more favora-
ble clinical profile, but without complete cardiac 
recovery. However, these patients continued to 
experience significant HF symptoms, signs, and 
clinical complications, including several cardiac 
hospitalizations and mortality during the follow-up 
[12]. Moreover, clinical deterioration and recur-
rence of cardiac dysfunction when medical and 
device support were discontinued was described 
[17, 18]. Basuray et al. [7] showed that in patients 
with HFrecEF, that there is persistent neuro-
hormonal activation, increased oxidative stress, 
and cardiomyocyte injury and stress despite ap-
parent LVEF recovery. Event-free survival in 
the HFrecEF group was better than that in the 
HFrEF and HFpEF groups but the symptoms and 
the risk of hospitalization were similar to those of 
the HFpEF population. In this study, statistically 
significant differences were not observed in the 
prognosis of patients with HFrEF or HFpEF, which 
is in agreement with previous publications from the 
present group [6, 19]. 
In the baseline HFrEF population a mean 
LVEF increase of 10%was observed. This finding 
was consistent with results described by Wilcox 
et al. [20]. From an individual patient perspec-
tive, a question arises from present results as to 
whether it is better to use LVEF higher than 40% 
or the LVEF recovery magnitude as in the index. 
A better prognosis was seen in patients with an 
increase in LVEF that was greater than 20%, which 
is similar to that reported in the super-responder 
patients treated with a cardiac-resynchronization 
device [21]. Thus, the LVEF baseline level and 
the recovery magnitude can play complementary 
roles. The indication for battery replacement in 
patients with a cardiac resynchronization device 
who had also recovered LVEF is questioned in 
recent ESC Heart Failure Guidelines [4]. This is 
an important issue from a clinical and economic 
perspective. Despite the absence of relevant 
publications regarding this recommendation, 
the present results describe a patient population 
that can be affected and better prognoses can be 
seen in this HFrecEF population, reinforcing this 
guideline recommendation. Current knowledge is 
limited, so this decision needs to be individualized 
according to the clinical-demographic and socio-
economic determinants.
Table 4. Independent prognostic factors of left 
ventricular ejection fraction recovery.
Hazard 
ratio
95%  
confidence 
interval
P
Age 0.957 0.939–0.976 < 0.001
NYHA III–IV 0.422 0.199–0.893 0.024
ACEIs and BB 2.126 1.349–3.349 0.001
Ischemic  
etiology 
0.385 0.224–0.662 0.005
ICD 0.285 0.02–0.990 0.048
Constant 2.428 0.270
ACEIs — angiotensin-converting enzyme inhibitors; BB — beta-
-blockers; ICD — implantable cardioverter-defibrillator; NYHA — 
New York Heart Association
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If a CRT is indicated, it is necessary for pa-
tients to be receiving optimal medical therapy for at 
least 3 months and to maintain a reduced LVEF [4]. 
Results herein suggest that CRT implantation 
based on a remote LVEF assessment can over-
estimate the proportion of patients who require 
a CRT and islikely because of the LVEF recovery 
effect during follow-up after treatment optimization.
In this study, LVEF recovery was an inde-
pendent predictor of mortality in a multivariate 
analysis. The mortality risk was 2.2-times higher 
in HFpEF patients and in patients who continued to 
have a reduced LVEF, compared with patients with 
HFrecEF (Table 2). Age and BNP levels were also 
independent predictors of mortality in multivari-
ate analysis [22–25]. Additionally, LVEF recovery 
was an independent predictor of survival free of 
hospitalization compared with  HFpEF and HFrEF 
patients (Table 3). This finding was not observed 
in Basuray et al. [7]; the differences between both 
patient populations may explain the differences in 
these results.
Five variables were identified as predictors of 
LVEF recovery and LVEF that remained depressed 
(< 40%). The probability of LVEF recovery was 
reduced with advancing age, as was previously 
described [23, 24]; the highest capacity for revers-
ing remodeling in younger patients can influence 
this finding. It also also showed that patients with 
advanced NYHA functional classes had a lower 
probability of LVEF recovery [26].
In this study, treatment with ACEIs and beta-
blockers was the strongest predictor of LVEF re-
covery. These drugs have shown a favorable effect 
on patient survival and decreased morbidity [27, 
28] in patients with HFrEF, they also improve car-
diac remodeling factors [29], which may contribute 
to explaining the LVEF recovery process.
The interaction between the HF ischemic eti-
ology and the lower probability of LVEF recovery 
may be influenced by the presence of myocardial 
viability [30] and a limited number of ventricular 
viable segments compared with patients with HF 
resulting from primary dilated cardiomyopathy 
[20]. Moreover, the amount of the LVEF increase 
associated with medical therapy (ACEIs and beta-
blockers) was lower in patients with ischemic 
cardiomyopathy compared with HF patients with 
non-ischemic etiologies [31]. Ischemic etiology 
was more frequent in the present group of patients 
who maintained HFrEF during the follow-up, and 
non-ischemic causes (hypertensive, alcoholic, and 
primary dilated cardiomyopathy) were more fre-
quent in HFrecEF patients possibly because of the 
higher capacity for myocardial reverse remodeling 
that is associated with non-ischemic HF patients.
Finally, the previous ICD implantation was as-
sociated with a lower probability of LVEF recovery. 
The role of CRT on LVEF recovery is well known 
[21] and there is no evidence on the recovery in 
patients with ICD [32]. However, the results may 
be influenced by the present study characteristics 
with patients who had more advanced myocardial 
damage undergoing ICD implantation. This may 
significantly influence the finding that ICD implan-
tation is a marker of non-recovery.
Limitations of the study
Heart failure classification according to the 
LVEF is based on a consensus, and there are dis-
crepancies between different clinical guidelines 
and expert position papers [4, 25].
Left ventricular ejection fraction assessed by 
echocardiography was used to classify patients and for 
follow-up, and the technique variability in this method 
may have influenced these results, even though all 
the echo studies were performed by cardiologists 
with experience in cardiac imaging. This study fo-
cused on LVEF changes, and other cardiac structure 
and function parameters which were not assessed.
Patients were included in the registry during 
their first consultation in the indicated HF outpa-
tient clinics, but there was no precise information 
on the duration of the HF process. The present 
findings are limited to a cohort of patients who had 
a chronic HF condition and LVEF re-evaluation 
after a 1-year period; a more prolonged follow-up 
period could increase the number of patients in 
the HF-recovered group, or patients with LVEF 
recovery early after treatment optimization could 
undergo deterioration during a more prolonged 
observation period. 
Because of the relatively small size of our 
HFrecEF group treated with CRT, there is insuf-
ficient data to analyze predictors of device response 
or to determine the specific prognosis of CRT 
responders. 
The proportion of patients without LVEF as-
sessment after a 1-year follow-up may have influ-
enced the present findings, although high mortality 
during this follow-up period (Suppl. Table 1, Fig. 4) 
identifies a group of patients with a poor prognosis, 
which would partially explain why they did not have 
an echocardiographic control. 
The prospective follow-up of these patients is 
one of the strengths of this study. A retrospective se-
lection and classification of the patients can be a lim-
itation in similar, previously published studies [7]. 
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The design of this study probably reduced patient 
misclassification and may offer more precise infor-
mation on the real prevalence of HFrecEF.
Conclusions
In a cohort of patients with HFrEF, the recov-
ery process identifies a group of patients with an 
improved prognosis compared with the patients 
who maintained a decreased LVEF during follow-
up, particularly in those with a LVEF increase 
higher than 20%. Treatment with ACEIs and beta-
-blockers along with the NYHA functional class 
were the strongest predictors of LVEF recovery. 
This study underscores the need for further inves-
tigation of the pathophysiologic characteristics as-
sociated with the recovery process, to better tailor 
therapy and extend the period of disease remission.
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